Apollomics
An innovative biopharmaceutical company committed to the discovery and development of oncology combination therapies.
Launch date
Employees
Market cap
CAD20.4m
Enterprise valuation
(CAD9m) (Public information from Sep 2024)
Share price
$0.127 APLM
Pleasanton California (HQ)
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | - | - | - | - | <1m | 1.0m | - |
| % growth | - | - | - | - | - | 100 % | - |
| EBITDA | (73.5m) | (91.1m) | (239m) | (174m) | (42.1m) | (76.6m) | (127m) |
| % EBITDA margin | - | - | - | - | (8420 %) | (7660 %) | - |
| Profit | (74.8m) | (94.8m) | (241m) | (173m) | (65.3m) | (94.7m) | (145m) |
| % profit margin | - | - | - | - | (13052 %) | (9470 %) | - |
| EV / revenue | - | - | - | - | 26.4x | 38.1x | - |
| EV / EBITDA | - | -1.4x | -0.6x | -0.5x | -0.3x | -0.5x | -0.3x |
| R&D budget | 31.4m | 35.6m | 35.5m | 34.2m | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - |
| N/A | - |
| N/A | $5.0m | Seed | |
N/A | Spinout | ||
$9.8m | Series A | ||
$100m | Series B | ||
* | $124m | Series C | |
* | $104m Valuation: $899m -9.9x EV/LTM EBITDA | SPAC IPO | |
* | N/A | $23.7m | Post IPO Equity |
* | N/A | $6.0m | Private Placement VC |
| Total Funding | CAD334m | ||
Related Content
Recent News about Apollomics
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.
